Targeting Inflammatory Pathways: Personalized Approaches for Severe Asthma – Your Questions Answered I

March 21, 2016
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program content and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of ACAAI. 

All identified conflicts of interest have been resolved. 


PLANNING COMMITTEE
Bobby Q. Lanier, MD, FACAAI 
Executive Medical Director 
American College of Allergy, Asthma & Immunology 
Clinical Professor of Pediatrics 
University of North Texas Health Science Center 
Fort Worth, TX 

Supported/Contracted Research: Merck, Novartis, Teva; Speaker: Genentech, Merck 

Program Chair and Moderator
Bradley E. Chipps, MD, FACAAI
Medical Director, Respiratory Therapy and Cystic Fibrosis Center 
Sutter Medical Center 
Capital Allergy & Respiratory Disease Center 
Sacramento, CA 

Consultant/Advisor, Speaker: AstraZeneca, Boehringer Ingelheim, Genentech, Meda, Merck, Novartis 

PROGRAM FACULTY 
Rohit K. Katial, MD, FACAAI
Professor of Medicine 
Associate Vice President of Clinical Research & Industry Relationships 
Co-Director, Asthma Institute 
Helen Wohlberg & Herman Lambert Chair in Pharmacokinetics  
Department of Medicine  
National Jewish Health 
Denver, CO 

Consultant/Advisor: AstraZeneca, GlaxoSmithKline, Meda, Teva; Speaker: AstraZeneca, Meda, Teva; Supported/Contracted Research: AstraZeneca, Teva 

Stephen P. Peters, MD, PhD
Thomas H. Davis Chair in Pulmonary Medicine 
Chief, Section on Pulmonary, Critical Care, Allergy & Immunologic Diseases 
Wake Forest School of Medicine 
Executive Director, Respiratory Service Line, Wake Forest Baptist Health 
Wake Forest Baptist Medical Center 
Winston-Salem, NC 

Consultant/Advisor: Array Biopharma, Aerocrine, Airsonett AB, AstraZeneca, Boehringer Ingelheim, Catalyst Biosciences, Experts in Asthma, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, Ono, Pfizer, PPD, Quintiles, Sunovion, Teva and Theron; Speaker: Merck; Supported/Contracted Research: American Lung Association, National Institutes of Health (NHLBI & NIAID), Actavis, Actelion, Amgen, AstraZeneca, Boehringer Ingelheim, Janssen Biotech, Genentech, GlaxoSmithKline, MedImmune, Novartis and Sanofi 

Education and Publishing Staff/Committee/Reviewers have no relevant financial relationships to disclose, except as may be listed above. 

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
Course opens: 
03/21/2016
Course expires: 
03/20/2018
Event starts: 
03/21/2016 - 7:00pm
Event ends: 
03/21/2016 - 7:30pm
Cost:
$0.00
Rating: 
0

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance

Accreditation Period

Course opens: 
03/21/2016
Course expires: 
03/20/2018

Price

Cost:
$0.00
Please login or create an account to take this course.